Clinical trials: Ranibizumab
Retinal Diseases
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
The purpose of this study in to compare the efficacy of treatment of diabetic macular edema (DME) using Ranibizumab (Lucenti®), Aflibercept (Eylea®) and Aflibercept (Eylea®) plus Ranibizumab (Lucentis®).
- Trial name
- NCT02646670
- Testing
- Ranibizumab, Aflibercept, Ranibizumab and Aflibercept
- Volunteers
- 20 people
- Sponsor
- Instituto de Olhos de Goiania
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Diabetes Mellitus, With Complications
New Concepts in Diabetic Macular Edema (DME)
Intravitreal ranibizumab injection procedure is simple and effective. In management of chronic DME there is no clear anatomical endpoint. Visual stability is the primary aim.
- Trial name
- DME (NCT04186702)
- Testing
- INTRAVITREAL RANIBIZUMAB INJECTION
- Volunteers
- 150 people
- Sponsor
- Ain Shams University
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity
Long Term Outcome of Intravitreal Ranibizumab for ROP
premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year were examined for refractive state and biometry
- Trial name
- NCT04537065
- Testing
- cycloplegic refraction
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Ameera Gamal Abdelhameed
Retinopathy of Prematurity
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
This study is a retrospective, multi-center real world study. The real world data comes from the electronic medical record system and disease database of the research centers .The patient's demographic information, disease…
- Trial name
- NCT04985448
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Retinopathy of Prematurity
Refractive Error and Biometry in Retinopathy of Prematurity
The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
- Trial name
- NCT03334513
- Testing
- Bevacizumab, Ranibizumab
- Volunteers
- 35 people
- Sponsor
- San Ni Chen
Exudative Age-Related Macular Degeneration
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative…
- Trial name
- ELOUAN (NCT02089503)
- Testing
- intravitreal injections of Lucentis
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Choroidal Neovascularization, Macular Degeneration
Photodynamic and Pharmacologic Treatment of CNV
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration…
- Trial name
- PBS (NCT00570193)
- Testing
- verteporfin (Visudyne), ranibizumab (Lucentis)
- Volunteers
- 41 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Retinopathy of Prematurity (ROP)
Rainbow Extension Study
The purpose of this study was to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study…
- Trial name
- RainbowExt (NCT02640664)
- Testing
- Ranibizumab
- Where
- 73 sites in United States, Austria and 22 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity (ROP)
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity: A Prospective Interventional Case Series
Aggressive posterior retinopathy of prematurity (AP-ROP) is a severe form of retinopathy of prematurity that can progress rapidly and lead to retinal detachment and permanent vision loss if not treated promptly.
- Trial name
- NCT07721298
- Testing
- Intravitreal Ranibizumab injection
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Ain Shams University
Retinopathy of Prematurity, Neurodevelopmental Abnormality
Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity
The goal of this research project is to identify the long-term outcome of neurodevelopment in patients with retinopathy of prematurity(ROP) and the treatment of anti-vascular endothelial growth factor (VEGF) such as intravitreal…
- Trial name
- NCT05186155
- Testing
- Severe ROP
- Where
- Taiwan
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Retinopathy of Prematurity
RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
- Trial name
- RAINBOW (NCT02375971)
- Testing
- Ranibizumab, Laser therapy
- Where
- 86 sites in United States, Austria and 24 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT00403039
- Testing
- Ranibizumab (Lucentis )
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Anti-VEGF Treatment, Ranibizumab
Effectiveness of Biosimilar Ranibizumab in the Management of Diabetic Macular Edema
Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes. Anti-VEGF agents are widely used to improve vision and reduce retinal swelling.
- Conditions
- Anti-VEGF Treatment, Ranibizumab, Biosimilar
- Trial name
- ERBDME (NCT07663370)
- Testing
- Ranibizumab biosimilar
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Benha University
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Pterygium
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
The purpose of this study is to evaluate the pterygium vascularity and size before and after intralesional ranibizumab injection and to evaluate its recurrence rate following pterygium excision surgery.
- Trial name
- NCT02342392
- Testing
- ranibizumab
- Volunteers
- 36 people
- Sponsor
- Universiti Sains Malaysia